More than 90 percent of people with the genetic condition Huntington’s disease develop chorea — involuntary movements that can interfere with daily activities, communication, and independence. While ...

Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...

Many people with Huntington’s disease experience chorea, but they are separate conditions. Chorea is one of several common symptoms of Huntington’s disease, but it has other potential causes. Chorea ...

A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

A drug widely available in Europe and Canada – but not the United States – dramatically eases one of the most disabling symptoms of Huntington’s disease, involuntary writhing movements known as chorea ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

The medications approved by the Food and Drug Administration (FDA) for treating Huntington’s disease chorea are Xenazine (tetrabenazine), Ingrezza (valbenazine) and Austedo (deuterabenazine).

This type of medication can help manage the uncontrolled movements that can occur with Huntington’s disease. Huntington’s disease is a neurodegenerative disorder that causes a progressive breakdown of ...

‌Chorea is a movement disorder that stems from something wrong with the basal ganglia nerve structure deep in your brain. It causes involuntary movements of the hands, feet, and face. These movements ...

Over 90 percent of people with Huntington’s disease develop chorea. Learn about FDA-approved VMAT2 inhibitors, off-label medications, and lifestyle strategies to manage involuntary movements.